Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
August 27 2019 - 7:30AM
Cure SMA and Cytokinetics (Nasdaq:CYTK) today announced the renewal
of their partnership to increase education, awareness, public
policy and fundraising for spinal muscular atrophy (SMA).
Cytokinetics will lend support for several of Cure SMA’s upcoming
initiatives at the national level and continues to support and
participate in events in its local community throughout the
year. Cytokinetics remains committed to serving the interests
of patients and caregivers fighting SMA, a genetic disease that
robs people of their physical strength and can take away their
ability to walk, eat or breathe.
This year Cytokinetics was a Platinum Sponsor of
the 2019 Annual SMA Conference, a unique event that brings together
families affected by SMA, along with researchers and clinicians, to
network, learn, and collaborate. The conference was held from June
28 – July 1, 2019 in Anaheim, CA. In addition, Cytokinetics
sponsored two local events to fundraise and raise awareness in the
Northern California community: Concert for a Cure in May and the
Northern California Walk-n-Roll in August. Cytokinetics is also
continuing its membership in the Cure SMA Industry Collaboration, a
partnership that brings together pharmaceutical companies, Cure
SMA, and other non-profit organizations, to share information,
ideas, and data. Participants in The Cure SMA Industry
Collaboration work together to address scientific, clinical and
regulatory topics that are critical to advancing drug development
in SMA to provide benefit to the broader SMA community. Finally,
Cytokinetics will sponsor the 2019 Hope on the Hill Congressional
Dinner, an annual event that unites families fighting SMA with
leaders from government and industry to increase disease awareness
and collaborate to advance potential treatments and to improve
patient care.
“We are grateful for Cytokinetics’ long-standing
partnership and look forward to continuing our work together,” said
Kenneth Hobby, President of Cure SMA. “The outlook for people
living with SMA is brighter than ever due to the commitment and
innovations arising from companies like Cytokinetics who are making
progress towards important new treatments. We appreciate their
continued dedication to our community.”
“We are proud to continue our partnership with
Cure SMA. There is no more appropriate time to publicly recommit to
the SMA community than at the culmination of SMA awareness month,”
said Robert I. Blum, President and Chief Executive Officer of
Cytokinetics. “We remain committed to pursuing new therapies that
may improve muscle function in people with SMA.”
About Cure SMA
Cure SMA is dedicated to the treatment and cure
of spinal muscular atrophy (SMA)—a disease that takes away a
person’s ability to walk, eat, or breathe. It is the number one
genetic cause of death for infants. Since 1984, we’ve directed and
invested in comprehensive research that has shaped the scientific
community’s understanding of SMA. We are currently on the verge of
breakthroughs that will strengthen bodies, extend life, and lead to
a cure. We have deep expertise in every aspect of SMA – from the
day-to-day realities to the nuances of care options – and until we
have a cure, we’ll do everything we can to support and advocate for
those affected by the disease. Learn more about how you can help us
reach a treatment and cure at www.cureSMA.org.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and best-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen Inc.
(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of an international
clinical trials program in patients with heart failure including
GALACTIC-HF and METEORIC-HF. Amgen holds an exclusive worldwide
license to develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization in Europe and
certain other countries. Cytokinetics is collaborating with
Astellas Pharma Inc. (Astellas) to develop reldesemtiv, a fast
skeletal muscle troponin activator (FSTA) for diseases of
neuromuscular dysfunction, including SMA and ALS. Astellas holds an
exclusive worldwide license to develop and commercialize
reldesemtiv. Licenses held by Amgen and Astellas are subject to
specified co-development and co-commercialization rights of
Cytokinetics. Cytokinetics is also developing CK-274, a novel
cardiac myosin inhibitor that company scientists discovered
independent of its collaborations, for the potential treatment of
hypertrophic cardiomyopathies. Cytokinetics continues its over
20-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics' and its partners'
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics' business outlined in Cytokinetics'
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:CytokineticsDiane WeiserVice President,
Corporate Communications, Investor Relations(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024